BTG3 and dermatomyositis: In contrast to our results, a retrospective cohort of 231 adult-onset DM patients found ANA-positive individuals had a markedly lower risk of malignancy within 3 years compared with ANA-negative patients (11% vs. 43%, OR 0.16) [38].